Using of Nanoparticles in treating of Hydatid Disease in Domestic Animals

Abstract

The parasite Echinococcus granulosus is the cause of unilocular hydatid disease, which is a serious health risk to people and domestic animals worldwide. Livestock with hydatid disease suffers substantial financial losses due to the slaughterhouse's disapproval of the diseased animal parts, productivity losses (such as lowered live weight gain, milk yield, reproductive rates, and hide and skin value), and expenses related to caring for both humans and animals. Because of the parasite's complex life cycle and the difficulties associated with traditional treatment techniques, new strategies are needed to handle this crippling illness more successfully. In the treatment of hydatid illness, nanomedicine and nanoparticles have shown great promise, providing new approaches to medication distribution, focused therapy, diagnosis, and control measures. The possible roles and applications of nanomedicine and nanoparticles in treating hydatid illness in domestic animals are reviewed in this article. Owing to their distinct physicochemical characteristics at the nanoscale, nanoparticles enable tailored medication administration, enhancing anthelmintic agent potency while reducing systemic side effects. Therapeutic drugs like praziquantel or albendazole can be encapsulated in these nanoparticles, allowing for improved permeability and retention at the location of the parasite cysts. Additionally, imaging agents and diagnostic instruments at the nanoscale enable. Additionally, nanotechnology offers avenues for developing innovative control measures, including environmental disinfection and targeted delivery of parasiticides. Collaborative efforts between researchers, veterinarians, and experts in nanotechnology are crucial to harnessing the full potential of nanoparticles and nanomedicine in effectively managing the infection in domestic animals.